Neumora Therapeutics
NMRA1.6401.86% ( +0.030 )
Neumora Therapeutics (NMRA)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disord...
- Open
- 1.620
- High
- 1.690
- Low
- 1.610
- Prev. Close
- 1.610
- Volume
- 392.47K
- Turnover
- 648.00K
- Avg Price
- 1.651
- Bid/Ask Ratio
- --
- Amplitude
- 4.97%
- 52wk High
- 3.650
- Volume Ratio
- 0.47
- Turnover Ratio
- 0.37%
Neumora Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 31, 2026Price forecast
$6.28283.08%
Forecast & RatingBuy
9analysts
- Strong buy55.56%
- Buy22.22%
- Hold11.11%
- Sell0.00%
- Strong sell11.11%
News
- benzinga_article · Jul 31 at 12:24 PM
Why Is BioAge Labs Stock Sinking Friday?
- Tip Ranks · Jul 27 at 09:55 AM
Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
- PUBT · Jul 27 at 06:03 AM
Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline
- Unusual Whales · Jul 27 at 06:02 AM
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
- PUBT · Jul 27 at 06:00 AM
Neumora plans NMRA-215 clinical trial in 2026 after favorable toxicology results
- Market Beat · Jul 24 at 05:26 AM
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA
